Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Recruiting 13Completed 5Active not recruiting 5Terminated 4Not yet recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Dermatologic 5Thoracic 2Head & Neck 2Genitourinary 2Tumor-Agnostic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1CNS 1Breast 1

Conditions

Melanoma 5Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 72Nivolumab 49Ipilimumab 29Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11binimetinib 10Radiotherapy 10Cyclophosphamide 10CTLA-4 Antigen 9fludarabine 7encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7lenvatinib 6durvalumab 6Paclitaxel 6Carboplatin 6tislelizumab 5relatlimab 5fludarabine phosphate 5dostarlimab 5Pemetrexed 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × relatlimab × Dermatologic × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Massachusetts General Hospital

Phase 2 Active not recruiting
36 enrolled
Dermatologic

Melanoma

NCT05418972 2026-02-05

Neo ReNi II

Melanoma Institute Australia

Phase 2 Active not recruiting
20 enrolled
Dermatologic

Melanoma

NCT03470922 2025-09-09

RELATIVITY-047

Bristol-Myers Squibb

Phase 2/3 Active not recruiting
714 enrolled 17 charts 1 FDA
Dermatologic

Melanoma, Neoplasms

NCT05625399 2025-08-24

RELATIVITY-127

Bristol-Myers Squibb

Phase 3 Active not recruiting
579 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡